Evidence map›Paper›PMID 30140035›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2019

The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy.

Yogesh M Bramhecha, Shaghayegh Rouzbeh, Karl-Philippe Guérard, Eleonora Scarlata, Fadi Brimo, Simone Chevalier, Lucie Hamel, Armen G Aprikian, Jacques Lapointe

Abstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. The impact of PTEN deletion and ERG rearrangement on recurrence after treatment for prostate cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yogesh M BramhechaDivision of Urology, Department of Surgery, McGill University and the Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Shaghayegh RouzbehDivision of Urology, Department of Surgery, McGill University and the Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Karl-Philippe GuérardDivision of Urology, Department of Surgery, McGill University and the Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Eleonora ScarlataDivision of Urology, Department of Surgery, McGill University and the Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Fadi BrimoDepartment of Pathology, McGill University and the Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Simone ChevalierDivision of Urology, Department of Surgery, McGill University and the Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Lucie HamelDivision of Urology, Department of Surgery, McGill University and the Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Armen G AprikianDivision of Urology, Department of Surgery, McGill University and the Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Jacques LapointeDivision of Urology, Department of Surgery, McGill University and the Research Institute of the McGill University Health Centre, Montreal, QC, Canada. jacques.lapointe@mcgill.ca.ORCID http://orcid.org/0000-0002-4586-8052

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer is a clinically heterogeneous disease and accurately risk-stratifying patients is a key clinical challenge. We hypothesized that the concurrent identification of the DNA copy number alterations 10q23.3 (PTEN) deletion and 16p13.3 (PDPK1) gain, related to the PI3K/AKT survival pathway, would improve prognostication. We assessed PTEN deletion status using fluorescence in situ hybridization (FISH) and evaluated its clinical significance in combination with the 16p13.3 gain in a set of 332 primary radical prostatectomy cases on a tissue microarray with clinical follow-up. The PTEN deletion was detected in 34% (97/287) of the evaluable tumors and was significantly associated with high Gleason grade group (P < 0.0001) and advanced pathological tumor stage (pT-stage, P < 0.001). The PTEN deletion emerged as a significant predictor of biochemical recurrence independent of the standard clinicopathologic parameters (hazard ratio: 3.00, 95% confidence interval: 1.81-4.98; P < 0.0001) and further stratified patients with low and intermediate risk of biochemical recurrence [Gleason grade group 1-2 (≤3 + 4), Gleason grade group 2 (3 + 4), pT2, prostate-specific antigen ≤ 10, low and intermediate CAPRA-S score; log-rank P ≤ 0.007]. A PTEN deletion also increased the risk of distant metastasis (log-rank, P = 0.001), further supporting its role in prostate cancer progression. Combining both 16p13.3 gain and PTEN deletion improved biochemical recurrence risk stratification and provided prognostic information beyond the established CAPRA-S score (co-alteration: hazard ratio: 4.70, 95% confidence interval: 2.12-10.42; P < 0.0001). Our study demonstrates the potential clinical utility of PTEN genomic deletion in low-intermediate risk patients and highlights the enhanced prognostication achieved when assessed in combination with another genomic biomarker related to the PI3K/AKT pathway, thereby supporting their promising usefulness in clinical management of prostate cancer.

Indexed as

3-Phosphoinositide-Dependent Protein KinasesAdultAgedBiomarkers, TumorDNA Copy Number VariationsHumansMaleMiddle AgedPrognosisProstatectomyProstatic NeoplasmsPTEN Phosphohydrolase3-Phosphoinositide-Dependent Protein KinasesBiomarkers, TumorPDPK1 protein, humanPTEN PhosphohydrolasePTEN protein, human

Identifiers

PMID30140035

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.